Entera Bio (Nasdaq:ENTX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ENTX 주식 개요

임상 단계 회사인 엔터라 바이오는 경구용 정제 형태가 치료 표준을 변화시킬 잠재력이 있는 미충족 의료 수요를 위한 경구용 펩타이드 또는 단백질 대체 요법을 개발하는 데 주력하고 있습니다.

ENTX 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

위험 분석

수익은 향후 3년간 연평균 72.9% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동성

의미 있는 시가총액이 없습니다. ( $76M )

+ 2 더 많은 위험

Entera Bio Ltd. 경쟁사

MediciNova

NasdaqGM:MNOV

US$68.2m

vTv Therapeutics

NasdaqCM:VTVT

US$56.7m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Leap Therapeutics

NasdaqCM:LPTX

US$71.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Entera Bio
과거 주가
현재 주가	US$1.87
52주 최고치	US$3.35
52주 최저치	US$0.52
베타	1.6
11개월 변경	-19.40%
3개월 변경 사항	21.43%
1년 변경 사항	128.02%
33년 변화	-67.65%
5년 변화	-44.35%
IPO 이후 변화	-70.22%

최근 뉴스 및 업데이트

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23

Recent updates

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05

Entera Bio EPS misses by $0.22

Nov 19

Entera Bio completes enrollment in Phase 2 trial of EB613 in Osteoporosis

Nov 09

주주 수익률

	ENTX	US Biotechs	US 마켓
7D	-11.4%	2.0%	-0.3%
1Y	128.0%	12.4%	22.3%

수익률 대 산업: ENTX 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: ENTX 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is ENTX's price volatile compared to industry and market?
ENTX volatility
ENTX Average Weekly Movement	14.1%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

안정적인 주가: ENTX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ENTX 의 주간 변동성( 15% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2009	18	Miranda Toledano	www.enterabio.com

임상 단계 회사인 엔터라 바이오는 경구용 정제 형태가 치료 표준을 변화시킬 잠재력을 지닌 미충족 의료 수요를 위한 경구용 펩타이드 또는 단백질 대체 요법 개발에 주력하고 있습니다. 이 회사는 위장관에서 펩타이드를 안정화시키는 동시에 혈류로의 흡수를 촉진하도록 설계된 경구 전달 기술인 N-Tab을 활용합니다. 폐경 후 골밀도가 낮고 골다공증 고위험군 여성을 위한 최초의 1일 1회 경구용 골형성(뼈 형성) 치료제로서 3상 개발에 진입한 EB613(경구용 PTH(1-34))은 첨단 제품 후보입니다.

Entera Bio Ltd. 기본 사항 요약

Entera Bio 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ENTX 기본 통계
시가총액	US$73.78m
수익(TTM)	-US$8.72m
수익(TTM)	n/a

0.0x

P/S 비율

-7.7x

P/E 비율

ENTX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ENTX 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$8.72m
수익	-US$8.72m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.24
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

ENTX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ENTX 주식 개요

보상

위험 분석

Entera Bio Ltd. 경쟁사

NasdaqGM:MNOV

US$68.2m

NasdaqCM:VTVT

US$56.7m

NasdaqGS:FIXX

US$54.3m

NasdaqCM:LPTX

US$71.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Recent updates

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New minor risk - Shareholder dilution

Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Third quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 3Q 2022)

Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program

Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting

New minor risk - Share price stability

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Ltd., Annual General Meeting, Sep 13, 2023

First half 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1H 2022)

Entera Bio Ltd Adds Haya Taitel to its Board of Directors

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Consensus revenue estimates decrease by 97%, EPS upgraded

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)

Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

No longer forecast to breakeven

Entera Bio Ltd. Announces U.S. Food and Drug Administration Acceptance of Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Price target decreased by 11% to US$6.00

Entera Bio Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates increase by 59%

Price target increased to US$9.50

Insufficient new directors

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio Ltd. Announces Fda Agreement for A Single Phase 3 Clinical Trial to Support an NDA for Eb613 for the Treatment of Osteoporosis

Entera Bio Ltd. Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Price target increased to US$7.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Sep 07, 2022

Entera Bio Ltd. Announces Executive Changes

Insufficient new directors

Entera Bio Ltd. Announces Departure of Dr. Phillip Schwartz, President of Research & Development to Pursue Outside Opportunities

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Entera Bio Ltd. Announces Appointment of Miranda Toledano as Chief Business Officer and Head of Corporate Strategy

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$6.75

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Entera Bio Ltd. to Report Fiscal Year 2021 Results on Mar 08, 2022

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Entera Bio Announces Successful EB613 End-Of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (Bone Mineral Density) as the Primary Endpoint

Consensus forecasts updated

Forecast to breakeven in 2024